← All trials
NCT07165223
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 17, 2025
- Primary completion
- Nov 10, 2026
- Completion date
- Nov 10, 2026
- First posted
- Sep 10, 2025
- Last posted
- Nov 25, 2025
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Gan and Lee Pharmaceuticals, USALead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.